

STUDY PROTOCOL

Open Access

Living with prostate cancer: randomised controlled trial of a multimodal supportive care intervention for men with prostate cancer

Suzanne K Chambers^{1,2*}, Robert U Newton³, Afaf Girgis^{1,4}, Lisa Nielsen², Stephen Lepore⁵, Cathrine Mihalopoulos⁶, RA Gardiner^{7,8}, Daniel A Galvão³ and Stefano Occhipinti^{1,9}

Abstract

Background: Prostate cancer is the most common male cancer in developed countries and diagnosis and treatment carries with it substantial morbidity and related unmet supportive care needs. These difficulties may be amplified by physical inactivity and obesity. We propose to apply a multimodal intervention approach that targets both unmet supportive care needs and physical activity.

Methods/design: A two arm randomised controlled trial will compare usual care to a multimodal supportive care intervention "Living with Prostate Cancer" that will combine self-management with tele-based group peer support. A series of previously validated and reliable self-report measures will be administered to men at four time points: baseline/recruitment (when men are approximately 3-6 months post-diagnosis) and at 3, 6, and 12 months after recruitment and intervention commencement. Social constraints, social support, self-efficacy, group cohesion and therapeutic alliance will be included as potential moderators/mediators of intervention effect. Primary outcomes are unmet supportive care needs and physical activity levels. Secondary outcomes are domain-specific and health-related quality of life (QoL); psychological distress; benefit finding; body mass index and waist circumference. Disease variables (e.g. cancer grade, stage) will be assessed through medical and cancer registry records. An economic evaluation will be conducted alongside the randomised trial.

Discussion: This study will address a critical but as yet unanswered research question: to identify a population-based way to reduce unmet supportive care needs; promote regular physical activity; and improve disease-specific and health-related QoL for prostate cancer survivors. The study will also determine the cost-effectiveness of the intervention.

Trial Registration: ACTRN12611000392965

Background

Prostate cancer is the most common male cancer in developed countries (excluding non-melanoma skin cancer) [1]. In 2004 nearly 100,000 Australian men were living with a diagnosis [2]; and in Australian men aged 60 years and over, prostate cancer accounted for 4.9% of total disability-adjusted life years (DALYs) and 17.8% of cancer-related DALYs as at 2003 [3]. With increasing incidence and 10-year survival currently around 77% [2] the large cohort of men in our community living with

the sequelae of diagnosis is increasing. Therefore, the well-being of men with prostate cancer is of high public health significance.

Side effects of treatment for prostate cancer include urinary incontinence, bowel and erectile dysfunction [4]. In a recent longitudinal study assessing 1649 men diagnosed with prostate cancer three years previously, relative to a healthy aged matched population, each of the main treatments led to persistent negative effects on disease-specific quality of life (QoL) [5]. Across all treatments 36% to 87% of men reported erectile dysfunction; after radical prostatectomy 12% of men had persistent urinary incontinence; and 15% of men who had external

* Correspondence: suzanne.chambers@griffith.edu.au

¹Griffith Health Institute, Griffith University, Gold Coast, Australia
Full list of author information is available at the end of the article

beam radiotherapy had moderate/severe bowel problems. Unmet supportive care needs are highly prevalent in men with prostate cancer: more than half (54%) of men with prostate cancer express some level of unmet psychological need and 47% express unmet sexuality needs [6]. Three of the 10 most frequently reported unmet needs relate to sexuality, three to psychological concerns, and two each in the physical/daily living and health system and information domains. Need was greatest in those with poor health; the gradients in odds ratios of unmet need were up to five-fold between best and poorest health groups. Hence there is a link between overall health and unmet supportive care needs.

Relevant to this, most men diagnosed in Australia are over 55 years of age; many experience co-morbid chronic illness such as cardiovascular disease; and many are overweight and sedentary. There is emerging evidence that obesity is related to a higher risk of biochemical recurrence and prostate-cancer specific death for men with prostate cancer [7,8]. Higher levels of physical activity and muscle strength may enhance men's ability to regain and manage urinary and bowel symptoms and improve erectile function. A cross-sectional study [9] reported that for men who received external beam radiation therapy within the past 18 months, levels of physical activity were positively associated with sexual functioning. Wolin (2009) [10] found lower incontinence in prostate cancer survivors who were normal weight and physically active compared to survivors who were obese and sedentary. They also reported that after 58 weeks post-surgery the incidence of incontinence was the same for overweight but physically active men compared to normal weight but sedentary men. Thus, interventions seeking to make a significant impact on the well-being of men who have been previously treated for prostate cancer should assess the potential for physical activity to improve outcomes.

To date no intervention research specifically targeting unmet supportive care needs after prostate cancer has been reported [11]. As well, only a few prospective exercise studies have been conducted with prostate cancer survivors [12-16], and none of these examined unmet supportive care needs. Accordingly, in this trial we apply a multimodal intervention approach that targets both unmet supportive care needs *and* physical activity. We do this by using two main strategies: self-management and group peer support. Self-management interventions have shown consistent positive effects across a range of chronic illnesses and have great potential as a cost effective method of providing support to people affected by cancer; and address issues of equity, accessibility and choice. In addition, we uniquely trial the ability of remotely-delivered, tele-based group peer support to enhance the effectiveness of self-management for men with

prostate cancer. Peer support has relatively high uptake amongst men with prostate cancer with men reporting that peer discussions provide information, emotional support, and reduce feelings of social isolation [17]. We propose that adding group peer support to self-management will have increased efficacy through the mechanisms of social support; cognitive processing; lessening of stigma; and peer-based modelling of adaptive coping.

Methods/Design

Study Aims and Hypotheses

The overall study aim is to compare usual care to a multimodal supportive care intervention "Living with Prostate Cancer" that will combine self-management with tele-based group peer support. In doing so we will also compare the cost-effectiveness of the support intervention relative to usual care; and identify demographic, medical and psychosocial variables that predict improvement in adjustment in prostate cancer patients with the intervention approach. The study has two arms: 1) usual care; and 2) multimodal supportive care - self-management plus six months of monthly tele-based group peer support.

It is hypothesised that 3, 6 and 12 months after recruitment and commencement of the intervention:

1. Relative to men who receive usual care, men who receive the multimodal supportive care intervention will have: fewer unmet supportive care needs; greater improvements in quantity and quality of physical activity.
2. Intervention-driven improvements in unmet supportive care needs and physical activity will be mediated by self-efficacy and moderated by social constraints and social support.
3. For all men, those who show the greatest improvements over time in physical activity will also have the greatest improvements in unmet supportive needs; disease-specific and health-related QoL.
4. The multimodal supportive care intervention will be more cost-effective compared to usual care.

Intervention

Usual care will consist of the man's standard medical management and a package containing existing evidence-based patient education materials. The multimodal supportive care intervention "Living with Prostate Cancer" will include self-management and tele-based group peer support. All men in the multimodal intervention condition will receive a printed feedback sheet with baseline assessments of unmet need, their distress thermometer score, body mass index, waist circumference and physical activity levels. This will assist them to

identify potential target areas for improvement; evaluate prime concerns; and set self-management goals. As well, a password protected website will be developed utilising Web 2.0 technology to guide men through program materials and other relevant existing web-based resources in an interactive online environment. This will allow each man to access other topic areas should his needs change; locate misplaced resources; access other helpful resources; and interact with other men in the study.

The exercise module of the intervention will focus on low cost strategies that are easily implemented in any geographic area. Participants will be encouraged to meet the physical activity targets recommended for cancer survivors [18-20]. Each participant will be provided with an elastic exercise device (Gymstick, Finland) and a watch with heart rate monitor (Polar, Finland) so that all men have the basic equipment to pursue an effective exercise program even in rural or remote settings with no additional facilities.

The tele-based group peer support will be conducted through teleconference and will be co-facilitated by a nurse counsellor and experienced trained peer. A peer is a man who has been previously diagnosed with prostate cancer and who is physically and emotionally well enough to provide support to others. The focus of the peer support groups will be on sharing experiences to facilitate peer learning, coping self-efficacy, emotional/social support and processing of experiences. The groups will have up to eight members and will be formed as men are recruited. Groups will run for six months with monthly teleconferenced meetings.

Participants

With the strong endorsement and support of Queensland Urologists, recruitment will be undertaken through the Queensland Cancer Registry (QCR), a population-based register of cancer diagnoses in Queensland. Clinicians will be approached for permission to contact their patient about the study. Where the doctor has given permission for contact, those patients will be contacted for consent to be in the study [21,22]. Informed written consent will be obtained before study commencement and data collection. Figure 1 illustrates the recruitment, intervention and data collection process.

Inclusion criteria are that the men must: (1) have recently been diagnosed with localised prostate cancer (men will be three to six months post-diagnosis at recruitment); (2) be able to read and speak English; (3) have no previous history of head injury, dementia or psychiatric illness; (4) have no other concurrent cancer; (5) have phone access; and (6) have physician clearance to participate in the study. The diagnosing clinician will

assist in determining eligibility as part of the consent process through the QCR.

Approximately 590 men will be recruited to the study (allowing 15% attrition from treatment; 250 men in each condition will complete final assessments). According to a Monte Carlo simulation run through Mplus, this sample size will provide between 80-85% power to detect standardised intervention effect sizes of .5 (moderate) for the dichotomous outcomes even with completion rates of 70% that are lower than the projected 85%. Power for the continuous outcomes is naturally higher for the same sample sizes, as evidenced by simulations by Jo and colleagues [23].

Study Integrity

Ethical approval has been obtained from the Griffith University Human Research Ethics Committee (Approval: PSY/F6/10/HREC). The study design will be guided by the CONSORT criteria [24]. Randomisation to study condition will occur following the completion of baseline assessment. Assessments will be by telephone and self-report written questionnaires and project staff tracking assessments will be blinded to condition where possible. Randomisation will occur in blocks of 16, with each condition randomly generated 8 times within each block to ensure an unpredictable allocation sequence with equal numbers of men in each condition at the completion of each block; and sufficient men to form a tele-based group (of 6-8) in the multimodal supportive care condition. This sequence will be undertaken by the project manager and concealed from investigators. The group sessions will be audiotaped with 25% reviewed to ensure adherence to a peer support approach. Analyses will be conducted on the basis of intention to treat.

Measures

A series of previously validated and reliable self-report measures will be administered to men at four time points: baseline/recruitment (when men are approximately 3-6 months post-diagnosis) and at 3, 6, and 12 months after recruitment and intervention commencement. Baseline assessments will be conducted by telephone to facilitate completion of assessments prior to randomisation. Follow-up assessments will be conducted through written questionnaires that will be mailed to participants. Social constraints, social support, self-efficacy, group cohesion and therapeutic alliance will be included as potential moderators/mediators of intervention effect. Primary outcomes are unmet supportive care needs and physical activity levels. Secondary outcomes are domain-specific and health-related QoL; psychological distress; benefit finding; body mass index and waist circumference (the following list describes the measures




Figure 1 Flowchart of recruitment, intervention and assessment.

in detail). Disease variables (e.g. cancer Gleason score, stage) will be assessed through medical and cancer registry records.

Moderators/Mediators

Coping Self Efficacy Self-efficacy will be measured using a scale previously developed by Lepore and colleagues for men with prostate cancer [25]. This scale measures how certain men are that they will be able to control side effects, manage stress, understand their illness and communicate effectively with physicians and family.

Social Support Social support will be assessed using the MOS Social Support Survey [26].

Social Constraints The Social Constraints Scale (SCS) [27] will assess the extent that men perceive they cannot talk freely about cancer-related concerns and feelings with others. The SCS has good reliability and predicts adjustment to prostate cancer [28].

Group Cohesion Cohesion within the peer support groups will be measured with the Perceived Cohesion Scale [29].

Therapeutic Alliance The quality of the bond between the peers and men in the tele-based group peer sessions will be assessed by the Working Alliance Inventory [30].

Primary Outcome Variables

Unmet Supportive Care Needs The Supportive Care Needs Survey Short Form 34 (SCNS-SF34) will assess patients' need for help over the last month across 5 domains: psychological, health systems and information, patient care and support, physical and daily living, and sexuality needs [31]. It has well demonstrated reliability and validity in cancer populations. An 8-item prostate cancer-specific module will be added to the standard scale [32].

Physical Activity All men will complete the Godin Leisure-Time Exercise Questionnaire [33]. This questionnaire assesses the average frequency of mild, moderate and strenuous exercise during free time in a typical week. Motivational readiness for physical activity will be assessed with a four item scale that asks about current levels of physical activity and intention to become more physically active [34]. In addition, men in the intervention arm only will complete simple activity diaries assessing mode, duration and intensity of physical activity entering data from the heart rate watches provided for a seven day period at the baseline assessment before the intervention commences.

Secondary Outcome Variables

Domain Specific QoL The International Prostate Symptom Score [35] and symptom and bother subscales of the Expanded UCLA Prostate Cancer Index [36,37] will assess disease-specific QoL.

Health-related QoL The AQoL-8D examines health-related QoL over eight dimensions (e.g. independent

living, mental health, relationships) and allows a simple global utility score to be calculated [38] which is essential for the derivation of Quality-adjusted-life-years (QALYs). QALYs are a useful generic outcome in economic evaluation allowing inferences regarding value-for-money to be made.

Psychological Distress Brief Symptom Inventory-18 [39] will provide a global measure of current psychological distress with subscales of anxiety, depression and somatisation. Somatisation and anxiety have been found to be related to physical activity levels in colorectal cancer survivors [40].

Distress Screening The single item Distress Thermometer will assess global psychological distress [41,42].

Positive Adjustment Positive adjustment will be measured with the Posttraumatic Growth Inventory assessing perceived positive outcomes resulting from a diagnosis of cancer [43]. Domains include new possibilities, appreciation of life, personal strength, relating to others, and spiritual/religious change. This scale has been previously validated with cancer patients.

Body mass index (BMI) and waist circumference Participants will be asked to measure their body weight and height. BMI will be calculated as weight/(height × height). Waist circumference will be measured using a cloth tape measure provided to the men with their intervention materials. Both BMI and waist circumference have been validated as indicators of overweight or obesity and correlate with cardiovascular disease and metabolic syndrome risk [44]. Self-measured height, weight and waist circumference is accurate and valid if appropriate instruction is provided [45].

Economic Evaluation Variables Participants will be given a cancer care diary to fill-out with respect to all appointments and treatments they receive throughout the follow-up period. The diary includes utilisation and out-of-pocket costs for services such as hospitalisation, medication, other allied health consultations and use of alternative therapies. Items such as medications will be cross-checked against medical records to ensure all medications are captured. The diary also measures days out-of-role (including paid and unpaid work) as well as travel costs so that a broader economic societal perspective may be undertaken. These questionnaires have been found to be reliable in estimating resource use. In addition, research team and provider records will be used to determine the costs of the multimodal supportive care intervention. Measured resource use will be valued using existing unit costs from sources such as the Medical Benefit Schedule fee rates for medical attendances; AN-DRG costs of hospitalisation; and Australian Bureau of Statistics estimates of Australian earnings [46].

Group communication analysis The group peer support telephone sessions will be audio-taped and

transcribed to allow in-depth analysis of men's interactions during these group sessions.

Statistical Analyses

This study is a multivariate, two-condition randomised controlled trial with repeated measures across time and continuous and dichotomous outcome variables. The analysis of longitudinal differences in outcome will use two complementary statistical approaches: multilevel (mixed) modelling (MLM) and growth mixture modelling (GMM) as applied to randomised preventative interventions by Muthén [47]. These procedures allow the testing of typical group level predictions such as Hypothesis 1 that men in the intervention condition will have better outcomes than the usual care group. However, by incorporating the hierarchical structure of assessment points nested within individual men they further permit the true assessment of individual change in unmet needs and of the individual predictors of such change (Hypotheses 2 and 3). Consequently (and unlike traditional approaches), such models deal with the heterogeneity of responses, such as that expected in the outcomes of the proposed study, by including such variation as an explicit model term. MLM and GMM have the advantages of allowing use of all available data points, which maximizes power to detect effects and reduces bias owing to missing data in longitudinal studies.

The economic evaluation will be a cost-consequences analysis conducted from both the broad societal perspective and the narrower perspective of the health care sector [48]. The economic evaluation will compare any incremental costs of the intervention (costs accrued in the intervention arm compared to costs accrued in the control arm) to the full list of incremental outcomes. The AQoL-8D will allow utility values to be determined (which are used in calculating Quality-Adjusted Life Years (QALYs)) for a cost-utility analysis, which is a more optimal design since QALYs allow comparisons across conditions. The evaluation will include only the costs of intervention delivery (excluding development or research costs), to estimate the resource use required if the multimodal supportive care intervention were rolled-out into practice. Uncertainty in the cost and outcome data and sensitivity of economic evaluation results to the methods of evaluation chosen will be tested through extensive sensitivity analyses. Depending on the results of the evaluation a longer life-time horizon may also be adopted [49].

Discussion

This study will develop and evaluate a novel population-based intervention to reduce unmet supportive care needs; promote regular physical activity; and improve

disease-specific and health-related QoL for prostate cancer survivors. To our knowledge, to date no supportive care intervention studies have targeted unmet supportive care needs for men with prostate cancer; trialled peer support as a method of enhancing self-management in this setting; or been adequately powered and designed to look differentially at individual differences [11]. This research will overcome these limitations, plus evaluate the cost-effectiveness of such an intervention. The intervention will be able to be utilised in a range of settings including broad reach tele-health support programs; health websites; and through support services and support groups internationally. This means that project outputs will be immediately translatable into practice to improve the overall well being of men with prostate cancer.

Acknowledgements and Funding

This project was funded by Cancer Australia and *beyondblue* (ID APP1008320). SKC is supported by an Australian National Health and Medical Research Council Fellowship (ID 496003). We gratefully acknowledge the support of the Urological Society of Australia and New Zealand; of Mr Bill McHugh, Mr Spence Broughton and Mr Peter Dorman as consumer advisors; and of Ms Brigid Hanley and Ms Sylvia Burns as prostate cancer nurse advisors in the undertaking of this research.

Author details

¹Griffith Health Institute, Griffith University, Gold Coast, Australia. ²Viertel Centre for Research in Cancer Control, Cancer Council Queensland, Brisbane, Australia. ³Edith Cowan University Health and Wellness Institute, Edith Cowan University, Perth, Australia. ⁴Ingham Institute, South Western Sydney Clinical School, University of NSW, Sydney, Australia. ⁵Department of Public Health, Temple University, Philadelphia, USA. ⁶Deakin Health Economics, Deakin University, Melbourne, Australia. ⁷University of Queensland Centre for Clinical Research, University of Queensland, Brisbane, Australia. ⁸Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Australia. ⁹School of Psychology, Griffith University, Brisbane, Australia.

Authors' contributions

SKC, RUN and AG developed the study concept and aims and initiated the project. LN, SL, CM, RAG, DAG and SO assisted in further development of the protocol. SKC was responsible for drafting the manuscript. SKC, LN and SO will implement the protocol and oversee collection of the data. All authors contributed to the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 12 July 2011 Accepted: 27 July 2011 Published: 27 July 2011

References

1. Baade PD, Youlden DR, Krnjacki LJ: International epidemiology of prostate cancer: geographical distribution and secular trends. *Mol Nutr Food Res* 2009, **53**(2):171-184.
2. Australian Institute of Health and Welfare, Australasian Association of Cancer Registries: Cancer survival and prevalence in Australia: cancers diagnosed from 1982 to 2004. Cancer Series no. 42. Cat. no. CAN 38. Canberra: AIHW; 2008.
3. Begg S, Vos T, Barker B, Stevenson C, Stanley L, Lopez AD: The burden of disease and injury in Australia 2003. Cat. No. PHE 82. Canberra: AIHW; 2007.
4. Eton DT, Lepore SJ: Prostate cancer and health-related quality of life: a review of the literature. *Psychooncology* 2002, **11**(4):307-326.
5. Smith DP, King MT, Egger S, Berry MP, Stricker PD, Cozzi P, Ward J, O'Connell DL, Armstrong BK: Quality of life three years after diagnosis of

- localised prostate cancer: population based cohort study. *BMJ* 2009, **339**:b4817.
6. Smith DP, Supramaniam R, King MT, Ward J, Berry M, Armstrong BK: **Age, health, and education determine supportive care needs of men younger than 70 years with prostate cancer.** *J Clin Oncol* 2007, **25**(18):2560-2566.
 7. Magheli A, Rais-Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M, Gonzalzo ML: **Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching.** *Urology* 2008, **72**(6):1246-1251.
 8. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW, Donahue TF, Foley JP, Chung AK, McLeod DG: **Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.** *J Clin Oncol* 2004, **22**(3):439-445.
 9. Dahn JR, Penedo FJ, Molton I, Lopez L, Schneiderman N, Antoni MH: **Physical activity and sexual functioning after radiotherapy for prostate cancer: beneficial effects for patients undergoing external beam radiotherapy.** *Urology* 2005, **65**(5):953-958.
 10. Wolin KY, Luly J, Sutcliffe S, Andriole GL, Kibel AS: **Risk of urinary incontinence following prostatectomy: the role of physical activity and obesity.** *J Urol* 2009, **183**(2):629-633.
 11. Chambers SK, Pinnock C, Lepore SJ, Hughes S, O'Connell DL: **A systematic review of psychosocial interventions for men with prostate cancer and their partners.** *Patient Educ Couns* 2011, Epub 22 February.
 12. Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, Venner PM, Quinney HA, Jones LW, D'Angelo ME, Wells GA: **Resistance exercise in men receiving androgen deprivation therapy for prostate cancer.** *J Clin Oncol* 2003, **21**(9):1653-1659.
 13. Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud'Homme DG, Malone SC, Wells GA, Scott CG, Slovincic D'Angelo ME: **Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer.** *J Clin Oncol* 2009, **27**(3):344-351.
 14. Windsor PM, Nicol KF, Potter J: **A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma.** *Cancer* 2004, **101**(3):550-557.
 15. Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU: **Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.** *J Clin Oncol* 2010, **28**(2):340-347.
 16. Galvao DA, Nosaka K, Taaffe DR, Spry N, Kristjansson LJ, McGuigan MR, Suzuki K, Yamaya K, Newton RU: **Resistance training and reduction of treatment side effects in prostate cancer patients.** *Med Sci Sports Exerc* 2006, **38**(12):2045-2052.
 17. Steginga SK, Pinnock C, Gardner M, Gardiner RA, Dunn J: **Evaluating peer support for prostate cancer: the Prostate Cancer Peer Support Inventory.** *Brit J Urol Int* 2005, **95**(1):46-50.
 18. Newton RU, Galvao DA: **Exercise in prevention and management of cancer.** *Curr Treat Options Oncol* 2008, **9**(2-3):135-146.
 19. Hayes SC, Spence RR, DA G, Newton RU: **Australian Association for Exercise and Sport Science position stand: optimising cancer outcomes through exercise.** *J Sci Med Sport* 2009, **12**(4):428-434.
 20. Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvão DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A, Schneider CM, von Gruenigen VE, Schwartz AL: **American College of Sports Medicine. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors.** *Med Sci Sports Exerc* 2010, **42**(7):1409-1426.
 21. Hawkes AL, Pakenham KI, Courneya KS, Gollschewski S, Baade P, Gordon LG, Lynch BM, Aitken JF, Chambers SK: **A randomised controlled trial of a tele-based lifestyle intervention for colorectal cancer survivors ('CanChange'): study protocol.** *BMC Cancer* 2009, **9**:286.
 22. Aitken JF, Elwood M, Baade PD, Youl P, English D: **Clinical whole-body skin examination reduces the incidence of thick melanomas.** *Int J Cancer* 2010, **126**(2):450-458.
 23. Jo B: **Statistical power in randomized intervention studies with noncompliance.** *Psychol Methods* 2002, **7**(2):178-193.
 24. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC, Lang T: **The revised CONSORT statement for reporting randomized trials: explanation and elaboration.** *Ann Intern Med* 2001, **134**(8):663-694.
 25. Lepore SJ, Helgeson VS: **Psychoeducational support group enhances quality of life after prostate cancer.** *Cancer Research Therapy and Control* 1999, **8**:81-91.
 26. Sherbourne CD, Stewart AL: **The MOS social support survey.** *Soc Sci Med* 1991, **32**(6):705-714.
 27. Lepore SJ: **Social Constraints construct and measurement.** 2010 [http://faculty.tc.columbia.edu/upload/sl2201/Social_Constraints_Scale.doc].
 28. Lepore SJ, Roberts K, Helgeson VS: **Psychoeducational group interventions attenuate the positive relation between inadequate social resources and depressive symptoms in men treated for prostate cancer.** *Society of Behavioral Medicine 31st Annual Meeting Seattle, 7-10 April; 2010*.
 29. Bollen KA, Hoyle RH: **Perceived cohesion: A conceptual and empirical examination.** *Soc Forces* 1990, **69**(2):479-504.
 30. Hatcher RL, Gillaspay A: **Development and validation of a revised short version of the Working Alliance Inventory.** *Psychotherapy Research* 2006, **16**(1):12-25.
 31. Boyes A, Girgis A, Lecathelinais C: **Brief assessment of adult cancer patients' perceived needs: development and validation of the 34-item Supportive Care Needs Survey (SCNS-SF34).** *J Eval Clin Pract* 2009, **15**(4):602-606.
 32. Steginga SK, Occhipinti S, Dunn J, Gardiner RA, Heathcote P, Yaxley J: **The supportive care needs of men with prostate cancer.** *Psychooncology* 2001, **10**(1):66-75.
 33. Godin G, Shephard RJ: **A simple method to assess exercise behavior in the community.** *Can J Appl Sport Sci* 1985, **10**(3):141-146.
 34. Clark MM, Novotny PJ, Patten CA, Rausch SM, Garces YI, Jatoi A, Sloan JA, Yang P: **Motivational readiness for physical activity and quality of life in long-term lung cancer survivors.** *Lung Cancer* 2008, **61**(1):117-122.
 35. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskevitz RC, Holtgrewe HL, Mebust WK, Cockett AT: **The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.** *The Journal of Urology* 1992, **148**(5):1549-1557.
 36. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH: **The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure.** *Med Care* 1998, **36**(7):1002-1012.
 37. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG: **Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.** *Urology* 2000, **56**(6):899-905.
 38. Richardson J, Khan M, Iezzi A, Sinha K, Mihalopoulos C, Herrman H, Hawthorne G, Schweitzer I: **The AQoL-8D (PsyQoL) MAU instrument: Overview (Research Paper 39).** Melbourne: Centre for Health Economics, Monash University; 2009.
 39. Derogatis LR: **BSI-18: Administration, Scoring and Procedures Manual.** Minneapolis MN: National Computer Systems; 2000.
 40. Chambers SK, Lynch BM, Aitken J, Baade P: **Relationship over time between psychological distress and physical activity in colorectal cancer survivors.** *J Clin Oncol* 2009, **27**(10):1600-1606.
 41. National Comprehensive Cancer Network Inc: **Practice Guidelines in Oncology-v.1.2002: Distress Management (Rep. No. Version 1).** Fort Washington, PA: National Comprehensive Network Inc; 2002.
 42. National Breast Cancer Centre: **How are you travelling? Understanding the emotional and social impact of cancer.** Camperdown, NSW: National Breast Cancer Centre; 2007.
 43. Tedeschi RG, Calhoun LG: **The Posttraumatic Growth Inventory: measuring the positive legacy of trauma.** *J Trauma Stress* 1996, **9**(3):455-471.
 44. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SCJ, Spertus JA, Costa F: **Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.** *American Heart Association Circulation* 2005, **112**(17):2735-2752.
 45. Elliott WL: **Criterion validity of a computer-based tutorial for teaching waist circumference self-measurement.** *Journal of Bodywork and Movement Therapies* 2008, **12**:133-145.
 46. Commonwealth Department of Health and Ageing: **Manual of resource items and their associated costs.** Canberra: Australian Government; 2002.
 47. Muthen B, Brown CH, Masyn K, Jo B, Khoo ST, Yang CC, Wang CP, Kellam SG, Carlin JB, Liao J: **General growth mixture modeling for randomized preventive interventions.** *Biostatistics* 2002, **3**(4):459-475.

48. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL: **Methods for the Economic Evaluation of Health Care Programmes.** Oxford: Oxford University Press, Third 2005.
49. Carter R, Vos T, Moodie M, Haby M, Magnus A, Mihalopoulos C: **Priority setting in health: origins, description and application of the Australian Assessing Cost-Effectiveness initiative.** *Expert Rev Pharmacoecon Outcomes Res* 2008, **8**(6):593-617.

Pre-publication history

The pre-publication history for this paper can be accessed here:
<http://www.biomedcentral.com/1471-2407/11/317/prepub>

doi:10.1186/1471-2407-11-317

Cite this article as: Chambers *et al.*: Living with prostate cancer: randomised controlled trial of a multimodal supportive care intervention for men with prostate cancer. *BMC Cancer* 2011 **11**:317.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

